PT - JOURNAL ARTICLE AU - Mavrogeorgis, Emmanouil AU - Kondyli, Margarita AU - Mischak, Harald AU - Vlahou, Antonia AU - Siwy, Justyna AU - Rossing, Peter AU - Campbell, Archie AU - Mels, Carina MC AU - Delles, Christian AU - Staessen, Jan A AU - Latosinska, Agnieszka AU - Persu, Alexandre TI - Association of urinary peptides with hypertension AID - 10.1101/2023.12.14.23299991 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.14.23299991 4099 - http://medrxiv.org/content/early/2023/12/15/2023.12.14.23299991.short 4100 - http://medrxiv.org/content/early/2023/12/15/2023.12.14.23299991.full AB - BACKGROUND Hypertension is a common condition worldwide, yet its underlying mechanisms remain largely unknown. This study aims at identifying urinary peptides associated with hypertension to further explore its molecular pathophysiology.METHODS Peptidome data from 2876 individuals without end-organ damage were retrieved from the Human Urinary Proteome Database general population (discovery) or type 2 diabetic (validation) cohorts. Participants were divided based on systolic and diastolic blood pressure (SBP and DBP) into hypertensive (SBP≥140mmHg and/or DBP≥90mmHg) and normotensive (SBP<120mmHg and DBP<80mmHg, without antihypertensive treatment) groups. Differences in peptide abundance between the two groups were confirmed using an external cohort (n=420) of participants without end-organ damage, matched for age, body-mass index, eGFR, sex and presence of diabetes. Further, associations of the peptides with BP as a continuous variable were investigated. Findings were compared with peptide biomarkers of chronic diseases and bioinformatics analyses were conducted to potentially highlight the underlying molecular mechanisms.RESULTS Between hypertensive and normotensive individuals, ninety-six (mostly COL1A1 and COL3A1) peptides were found significantly different in the discovery (adjusted) as well as the validation (nominal significance) cohorts with consistent regulation. Of these peptides, 83 were also consistently regulated in the matched cohort. A weak, yet significant association between their abundance and standardized BP was also observed.CONCLUSIONS Hypertension is associated with an altered urinary peptide profile, with evident collagen differential regulation. Peptides related to vascular calcification and sodium regulation are also affected. Whether these modifications reflect the pathophysiology of hypertension per se and/or early subclinical target organ damage warrants further investigation.What is New?This is the first study demonstrating differential regulation of urinary peptides in hypertensive patients, independent from other co-factors like age, diabetes, or established kidney or cardiovascular disease.What is Relevant?The observed changes in urinary peptides indicate individual differences in molecular changes observed in hypertension, and may guide personalized treatment based on the observed molecular changesClinical/Pathophysiological Implications?The results indicate that collagen homeostasis may be a key molecular feature in hypertension and may serve as an attractive mechanism for pharmacological intervention.Competing Interest StatementH.M. is the founder and co-owner of Mosaiques Diagnostics (Hannover, Germany). E.M., J.S., and A.L. are employed by Mosaiques Diagnostics. P.R. has received grants from Astra Zeneca, Bayer, and Novo Nordisk; and honoraria (to Steno Diabetes Center Copenhagen) from Astra Zeneca, Abbott, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Gilead, and Sanofi.Funding StatementThis work was supported in part by the European Union's Horizon 2020 research and innovation programme (860329 Marie-Curie ITN ?STRATEGY-CKD?). Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. J.S. was supported via the following funding: The Non-Profit Research Association "Alliance for the Promotion of Preventive Medicine" (URL: www.appremed.org) received a non-binding grant from OMRON Healthcare, Inc. Ltd., Kyoto, JapanAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is based on published, publicly available and anonymized data and thus does not require further IRB approval as stated by the ethics committee of the Hannover Medical School, Germany, under the reference number: 3116-2016.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made available upon request directed to the corresponding author. Proposals will be reviewed and approved by the investigators and collaborators based on scientific merit. After approval of a proposal, data will be shared through a secure online platform after signing the data access and confidentiality agreement.